Researchers reveal immune mechanisms that drive development of rare allergic stomach disease
Researchers at Tel Aviv University have developed an experimental model to study eosinophilic gastritis, a rare allergic stomach disease. The study identifies immune pathways that could lead to more effective biologic therapies for patients.
Why it matters
Advancements in understanding rare diseases are critical for developing targeted treatments where options are currently limited.
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Experimental EoG induces eosinophil and mast-cell infiltration in the gastric mucosa. Credit: Allergy (2026). DOI: 10.1111/all.70420 Researchers at Tel Aviv University have developed one of the first experimental models that faithfully reproduces eosinophilic gastritis (EoG), a rare but increasingly recognized allergic disease of the stomach. Using this model, they identified the immune pathways responsible for driving the disease and explained why a new generation of biologic therapies currently being evaluated in clinical trials may benefit patients.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in